Bifogade filer
Kurs & Likviditet
Kalender
2024-11-07 | Kvartalsrapport 2024-Q3 |
2024-08-15 | Kvartalsrapport 2024-Q2 |
2024-05-16 | Kvartalsrapport 2024-Q1 |
2024-03-21 | Ordinarie utdelning ZEAL 0.00 DKK |
2024-03-20 | Årsstämma 2024 |
2024-02-27 | Bokslutskommuniké 2023 |
2023-11-09 | Kvartalsrapport 2023-Q3 |
2023-08-17 | Kvartalsrapport 2023-Q2 |
2023-05-11 | Kvartalsrapport 2023-Q1 |
2023-03-30 | Ordinarie utdelning ZEAL 0.00 DKK |
2023-03-29 | Årsstämma 2023 |
2023-03-02 | Bokslutskommuniké 2022 |
2022-11-10 | Kvartalsrapport 2022-Q3 |
2022-08-11 | Kvartalsrapport 2022-Q2 |
2022-05-12 | Kvartalsrapport 2022-Q1 |
2022-05-09 | Ordinarie utdelning ZEAL 0.00 DKK |
2022-04-06 | Årsstämma 2022 |
2022-03-10 | Bokslutskommuniké 2021 |
2021-11-11 | Kvartalsrapport 2021-Q3 |
2021-08-12 | Kvartalsrapport 2021-Q2 |
2021-05-12 | Kvartalsrapport 2021-Q1 |
2021-04-16 | Ordinarie utdelning ZEAL 0.00 DKK |
2021-04-15 | Årsstämma 2021 |
2021-03-11 | Bokslutskommuniké 2020 |
2020-11-12 | Kvartalsrapport 2020-Q3 |
2020-08-13 | Kvartalsrapport 2020-Q2 |
2020-05-14 | Kvartalsrapport 2020-Q1 |
2020-04-03 | Ordinarie utdelning ZEAL 0.00 DKK |
2020-04-02 | Årsstämma 2020 |
2020-03-12 | Bokslutskommuniké 2019 |
2019-11-14 | Kvartalsrapport 2019-Q3 |
2019-08-15 | Kvartalsrapport 2019-Q2 |
2019-05-16 | Kvartalsrapport 2019-Q1 |
2019-04-05 | Ordinarie utdelning ZEAL 0.00 DKK |
2019-04-04 | Årsstämma 2019 |
2019-03-07 | Bokslutskommuniké 2018 |
2018-11-15 | Kvartalsrapport 2018-Q3 |
2018-08-16 | Kvartalsrapport 2018-Q2 |
2018-05-16 | Kvartalsrapport 2018-Q1 |
2018-04-20 | Ordinarie utdelning ZEAL 0.00 DKK |
2018-04-19 | Årsstämma 2018 |
2018-03-07 | Bokslutskommuniké 2017 |
2017-11-08 | Kvartalsrapport 2017-Q3 |
2017-08-24 | Kvartalsrapport 2017-Q2 |
2017-05-17 | Kvartalsrapport 2017-Q1 |
2017-04-06 | Ordinarie utdelning ZEAL 0.00 DKK |
2017-04-05 | Årsstämma 2017 |
2017-03-15 | Bokslutskommuniké 2016 |
2016-11-09 | Kvartalsrapport 2016-Q3 |
2016-08-25 | Kvartalsrapport 2016-Q2 |
2016-05-18 | Kvartalsrapport 2016-Q1 |
2016-04-20 | Ordinarie utdelning ZEAL 0.00 DKK |
2016-04-19 | Årsstämma 2016 |
2016-03-16 | Bokslutskommuniké 2015 |
2015-11-05 | Kvartalsrapport 2015-Q3 |
2015-08-28 | Kvartalsrapport 2015-Q2 |
2015-05-22 | Kvartalsrapport 2015-Q1 |
2015-04-22 | Ordinarie utdelning ZEAL 0.00 DKK |
2015-04-21 | Årsstämma 2015 |
2015-03-12 | Bokslutskommuniké 2014 |
2014-11-07 | Kvartalsrapport 2014-Q3 |
2014-08-21 | Kvartalsrapport 2014-Q2 |
2014-05-06 | Kapitalmarknadsdag 2014 |
2014-04-29 | Kvartalsrapport 2014-Q1 |
2014-04-29 | Årsstämma 2014 |
2014-03-21 | Ordinarie utdelning ZEAL 0.00 DKK |
2014-03-20 | Bokslutskommuniké 2013 |
2013-11-15 | Kvartalsrapport 2013-Q3 |
2013-08-29 | Kvartalsrapport 2013-Q2 |
2013-05-15 | Kvartalsrapport 2013-Q1 |
2013-04-30 | Årsstämma 2013 |
2013-04-30 | Ordinarie utdelning ZEAL 0.00 DKK |
2013-03-14 | Bokslutskommuniké 2012 |
2012-11-29 | Kapitalmarknadsdag 2012 |
2012-04-26 | Ordinarie utdelning ZEAL 0.00 DKK |
2012-04-25 | Årsstämma 2012 |
2011-11-17 | Kvartalsrapport 2011-Q3 |
2011-10-25 | Kapitalmarknadsdag 2011 |
2011-08-18 | Kvartalsrapport 2011-Q2 |
2011-05-12 | Kvartalsrapport 2011-Q1 |
2011-04-29 | Ordinarie utdelning ZEAL 0.00 DKK |
2011-04-28 | Årsstämma 2011 |
Beskrivning
Land | Danmark |
---|---|
Lista | Large Cap Copenhagen |
Sektor | Hälsovård |
Industri | Bioteknik |
Press release – No. 07 / 2019
Zealand Pharma to attend Kempen Life Sciences Conference
Copenhagen, April 08, 2019 – Adam Steensberg, Interim Chief Executive Officer, will attend the Kempen Life Sciences Conference on April 16, 2019 in Amsterdam. Zealand Pharma is scheduled to present at 3:30 PM CET.
For further information, please contact:
Adam Steensberg, Interim Chief Executive Officer,
Executive Vice President and Chief Medical & Development Officer
Tel: +45 50 60 36 01, e-mail: ast@zealandpharma.com
Lani Pollworth Morvan, Investor Relations and Communications
Tel: +45 50 60 37 78, e-mail: lpm@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment